Larazotide (AT-1001)
Larazotide acetate (AT-1001) is a synthetic tight junction regulatory peptide derived from Vibrio cholerae zonula occludens toxin that modulates intestinal permeability by antagonizing the zonulin pathway, primarily investigated for celiac disease and intestinal barrier dysfunction.
Larazotide acetate (AT-1001) is a synthetic octapeptide that regulates intestinal tight junction permeability by antagonizing the zonulin receptor pathway. Originally derived from a fragment of the Vibrio cholerae zonula occludens toxin (Zot), larazotide was redesigned to function as a tight junction modulator rather than an opener, effectively reducing paracellular permeability in the small intestine.
Overview
Larazotide was developed from research on zonula occludens toxin (Zot), a protein produced by Vibrio cholerae that reversibly opens intestinal tight junctions. Alessio Fasano and colleagues at the University of Maryland identified the zonulin pathway as a key regulator of paracellular permeability and discovered that a modified fragment of Zot could antagonize rather than activate this pathway. This led to the development of AT-1001 (larazotide acetate) as a therapeutic agent to prevent tight junction opening in conditions characterized by increased intestinal permeability.
The zonulin pathway has been implicated in the pathogenesis of celiac disease, type 1 diabetes, inflammatory bowel disease, and other autoimmune conditions. In celiac disease, gliadin peptides trigger zonulin release from enterocytes, leading to tight junction disassembly and increased paracellular transport of immunogenic gluten fragments. Larazotide acts locally in the intestinal lumen to prevent this gliadin-induced permeability increase, representing a non-dietary adjunct therapy for patients on a gluten-free diet who continue to experience symptoms from inadvertent gluten exposure.
Mechanism of Action
Larazotide exerts its effects through targeted modulation of the tight junction complex:
- Zonulin receptor antagonism: Larazotide binds to the zonulin receptor on intestinal epithelial cells, preventing zonulin-mediated tight junction disassembly and maintaining the integrity of the paracellular barrier
- Tight junction protein stabilization: The peptide prevents gliadin-induced redistribution of tight junction proteins ZO-1 and occludin from the intercellular junction to the cytoplasm, preserving barrier architecture
- Actin cytoskeleton protection: By blocking the zonulin signaling cascade, larazotide prevents actin cytoskeletal rearrangement that normally accompanies tight junction opening
- Local luminal action: Larazotide acts primarily in the intestinal lumen with minimal systemic absorption, reducing the potential for off-target effects
- Gliadin-induced permeability blockade: Directly prevents the increase in paracellular permeability triggered by gliadin exposure in celiac-susceptible epithelium
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Intestinal Permeability and Barrier Function
Preclinical studies established that larazotide prevents gliadin-induced increases in intestinal permeability. In Ussing chamber experiments with human intestinal biopsies, Paterson et al. (2007) demonstrated that AT-1001 blocked the increase in transepithelial electrical resistance caused by gliadin peptides. Animal models confirmed that oral larazotide reduced intestinal permeability and prevented immune activation following gluten exposure.
Zonulin Pathway Biology
The discovery of zonulin as a human analog of Zot by Fasano et al. (2000) established the mechanistic basis for larazotide. Elevated zonulin levels have been associated with celiac disease, type 1 diabetes, and other autoimmune conditions. Larazotide's ability to antagonize this pathway without affecting baseline permeability makes it a targeted therapeutic with a favorable mechanism of action.
Beyond Celiac Disease
Preclinical research has explored larazotide's potential in other conditions involving increased intestinal permeability. Studies in type 1 diabetes models showed that AT-1001 reduced diabetes incidence in diabetes-prone BB rats by preventing autoimmune activation triggered by increased gut permeability. The peptide has also generated interest for inflammatory bowel disease, irritable bowel syndrome, and environmental enteropathy, though clinical data in these indications remain limited.
Celiac Disease Clinical Trials
Larazotide acetate has been evaluated in multiple Phase 2 clinical trials for celiac disease. A pivotal Phase 2b study (NCT01396213) by Leffler et al. (2015) enrolled 342 celiac patients on a gluten-free diet and demonstrated that 0.5 mg TID larazotide significantly reduced symptoms compared to placebo, with improvements in the Celiac Disease Gastrointestinal Symptom Rating Scale (CeD-GSRS). An earlier Phase 2a study by Kelly et al. (2013) showed that larazotide reduced intestinal permeability measured by lactulose-mannitol ratio during acute gluten challenge.
Safety Profile
Larazotide has demonstrated a favorable safety profile across multiple clinical trials. Because the peptide acts locally in the intestinal lumen with minimal systemic absorption, adverse events have been mild and gastrointestinal in nature (nausea, headache, abdominal pain), occurring at rates similar to placebo in Phase 2 studies. No dose-limiting toxicities have been identified across dose ranges of 0.25 mg to 8 mg TID. The local mechanism of action and lack of systemic exposure reduce the risk of off-target effects.
Clinical Research Protocols
- Dosing: Phase 2 trials tested 0.25 mg, 0.5 mg, 1 mg, 4 mg, and 8 mg TID (three times daily). The 0.5 mg TID dose showed optimal efficacy (PMID: 26026390).
- Duration: Phase 2 studies ranged from 2 weeks (gluten challenge) to 12 weeks (symptomatic relief).
- Routes: Oral capsule only. The peptide is designed to act in the intestinal lumen.
- Population: Adults with biopsy-confirmed celiac disease on a gluten-free diet for at least 12 months.
Subpopulation Research
- Celiac patients on GFD: Primary studied population. Leffler et al. (2015) enrolled patients with persistent symptoms despite gluten-free diet adherence (PMID: 26026390).
- Type 1 diabetes (preclinical): AT-1001 reduced diabetes incidence in BB rats by preventing permeability-mediated autoimmune activation (PMID: 16099460).
- Pediatric: Not yet studied in clinical trials, though celiac disease is commonly diagnosed in children.
- Non-celiac gluten sensitivity: Theoretical applicability given shared permeability mechanisms, but no clinical data available.
Pharmacokinetic Profile
- Half-life
- Acts locally in GI lumen; minimal systemic absorption
- Metabolism
- Expected proteolytic degradation in the distal intestine.
- Distribution
- Confined primarily to the GI lumen. Systemic levels are negligible at therapeutic doses.
- Oral
- Oral administration designed for luminal activity, not systemic bioavailability.
Ongoing & Future Research
- Phase 3 HEAL trial (NCT03569007): 9 Meters Biopharma's Phase 3 study evaluating larazotide 0.5 mg TID in celiac patients on a gluten-free diet.
- Exploration of larazotide for other conditions with impaired intestinal barrier function (IBD, IBS, environmental enteropathy).
- Investigation of zonulin as a biomarker for patient selection and treatment monitoring.
- Interest in combination approaches pairing barrier restoration with immune modulation.
Quick Start
- Route
- Oral capsule
Research Protocols
oral
Animal models confirmed that oral larazotide reduced intestinal permeability and prevented immune activation following gluten exposure. - Routes: Oral capsule only.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 0.25 mg, 8 mg | Per protocol | — |
| Dosing | 0.25 mg, 0.5 mg, 1 mg, 4 mg, 8 mg | Daily | — |
| Phase 3 HEAL trial (NCT03569007) | 0.5 mg | Per protocol | — |
| Population | 0.5 mg | Per protocol | 12 months |
Interactions
Peptide Interactions
Theoretical synergy for GI healing — larazotide restores tight junction integrity while BPC-157 promotes mucosal repair via VEGFR2 and NO pathways. No direct combination studies published.
Both target GI inflammation through different mechanisms — larazotide via barrier function, KPV via alpha-MSH anti-inflammatory signaling. Mechanistic rationale for combined intestinal repair.
What to Expect
What to Expect
Duration: Phase 2 studies ranged from 2 weeks (gluten challenge) to 12 weeks (symptomatic relief).
Population: Adults with biopsy-confirmed celiac disease on a gluten-free diet for at least 12 months.
Continued use as directed
Quality Indicators
What to look for
- Human clinical trials conducted
- Well-established safety profile
- Extensive peer-reviewed research base
Frequently Asked Questions
References (9)
- [9]Khaleghi S et al. The potential utility of tight junction regulation in celiac disease. Int Rev Cell Mol Biol (2016)
- [1]Fasano A et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet (2000)
- [2]Watts T et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci USA (2005)
- [3]Gopalakrishnan S et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides (2012)
- [4]Paterson BM et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects. Aliment Pharmacol Ther (1001)
- [5]Kelly CP et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge. Aliment Pharmacol Ther (2013)
- [6]Leffler DA et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet. Gastroenterology (2015)
- [7]Gopalakrishnan S et al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm (1002)
- [8]
Lactoferrin-Derived Antimicrobial Peptides (Lactoferricin, Lactoferrampin)
Lactoferricin and lactoferrampin are potent antimicrobial peptides derived from the N-terminal region of bovine and human lactoferrin, exhibiting broad-spectrum antimicrobial, anti-biofilm, anticancer, and antiviral activities through membrane-active mechanisms independent of iron binding.
Leu-Enkephalin
Leu-enkephalin (YGGFL) is an endogenous opioid pentapeptide and preferential delta-opioid receptor agonist involved in pain modulation, mood regulation, immune function, and stress response.